Ionis Pharmaceuticals applies proprietary antisense technology to tackle diseases at their genetic source, focusing on conditions such as FCS, Angelman syndrome, and HAE. The FDA approval of Tryngolza...

The FDA's nod to IONS' Tryngolza makes it the first approved treatment for FCS. It is also the company's first wholly-owned drug to receive marketing approval.

On Thursday, the FDA approved Ionis Pharmaceuticals, Inc.'s IONS Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, gen...

The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals' drug to treat a rare genetic disorder, making it the company's first wholly-owned drug, the health regulator's website showed ...

The mean of analysts' price targets for Ionis Pharmaceuticals (IONS) points to a 55.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

Ionis Pharmaceuticals (IONS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Ionis Pharmaceuticals (IONS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnin...

IONS reports better-than-expected top and bottom-line numbers for the third quarter of 2024.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q3 2024 Earnings Conference Call November 6, 2024 11:30 AM ET Company Participants Wade Walke – Senior Vice President of Investor Relations Brett Monia – Chi...

The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wa...

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.03 per share a year ago.

Besides Wall Street's top -and-bottom-line estimates for Ionis Pharmaceuticals (IONS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared...

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ionis is a promising biotech with a strong late-stage pipeline and lucrative Big Pharma partnerships, despite current weak commercial revenues and heavy losses. The company has five FDA-approved drugs...

AstraZeneca PLC (LSE:AZN) and Ionis Pharmaceuticals' (NASDAQ:IONS) drug Wainzua (eplontersen) has been recommended for approval in the European Union for treating hereditary transthyretin-mediated amy...